Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03447548
Other study ID # HHC-2017-0190
Secondary ID 1R33MH111850-01A
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2018
Est. completion date December 1, 2021

Study information

Verified date February 2024
Source Hartford Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community. This study looks to target a specific cognitive skill called processing speed to see if improving the ability to process information in a timely manner will improve social function in adolescents and young adults at risk for developing schizophrenia. Half will receive neurofeedback cognitive training targeting processing speed while the other half will receive an active control.


Description:

Processing speed deficits are characteristic of schizophrenia and related to its functional impairment, including in its nascent stages, during a putatively prodromal or clinical high risk period. These cognitive deficits have proven relatively refractory to pharmacologic strategies, though the deficits can be improved with cognitive remediation programs in schizophrenia. The cognitive gains can then generalize to functional improvement, particularly early in the course of illness (i.e. first episode psychosis). Although processing speed deficits are also prevalent in young people identified as at clinical high risk for psychosis (i.e. "psychosis risk syndrome"), and related to their concurrent impaired function and predictive of later psychosis (onset of which occurs in 20-25% of clinical high risk cohorts), little research has focused on how to remediate these deficits in clinical high risk patients. Remediating core cognitive deficits in clinical high risk patients could plausibly address present functional impairment in these young people and moderate illness progression. The investigators propose to conduct a double-blind randomized trial in 105 clinical high risk patients to examine a focal processing speed training program versus an active control in terms of improvement in processing speed and social function, and reduction in prodromal symptom severity.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date December 1, 2021
Est. primary completion date December 1, 2021
Accepts healthy volunteers No
Gender All
Age group 12 Years to 25 Years
Eligibility Inclusion Criteria: - Case identification and ascertainment depends on the fulfillment of the Criteria of Prodromal States as evaluated using the Structured Interview for Prodromal Syndromes: (1) attenuated positive symptom state which includes the emergence or worsening over the past year of non-psychotic disturbances in thought content, thought process or perceptual abnormality, (2) brief intermittent positive symptoms, and (3) genetic risk and deterioration. - Processing speed at least 0.5 Standard Deviation below the norm, as indexed by baseline performance on Digit Symbol Coding of 8 or below - Age range 12-25 (this age range also comprises the main period of risk for psychosis) - Written informed consent by patients >18 years old, and written assent by subjects <18 years old, with written informed consent by both parents (unless one is deceased or unavailable). Participants who turn 18 while in the study will be re-consented as adults through written informed consent. Exclusion Criteria: - Current or past diagnosis of psychotic disorder noted at baseline assessment (schizophrenia, schizophreniform, bipolar, schizoaffective, major depression with psychotic features, substance-induced psychosis, psychosis due to a medical condition. - Neurological, neuroendocrine or major medical disorders: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders (clinical interview), including seizure disorder and history of significant traumatic brain injury - Intelligence Quotient < 70: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders - Positive symptoms that occur only in the context of substance abuse or withdrawal (i.e. within one month), so as not to include those at risk for substance-induced psychotic disorder - Lack of fluency in English: subjects must speak English to complete behavioral assessments for which psychometric properties have been established in English, complete cognitive training, and in order to comprehend and comply with protocol requirements. - Substance abuse or dependence (including alcohol and marijuana) in previous six months: for purposes of standardization and interpretation of cognitive data.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Neurofeedback processing speed training
Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
Active control
Commercially available games on tablet

Locations

Country Name City State
United States Connecting Adolescents with Psychosis (CAP), Child & Adolescents Day Program Hartford Connecticut
United States Olin Neuropsychiatry Research Center Hartford Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Hartford Hospital National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change on the Wechsler Intelligence Scale Processing Speed Index Change on a paper and pencil test of processing speed Baseline, 1 month, 2 month, 6 month
See also
  Status Clinical Trial Phase
Terminated NCT03149107 - "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients" Phase 3
Recruiting NCT05131035 - Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk N/A
Completed NCT01269710 - Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study N/A
Enrolling by invitation NCT05567848 - Accelerated TMS in Psychosis Phase 1/Phase 2
Recruiting NCT03751865 - Early Detection and Intervention for Women At-risk of Psychosis N/A
Recruiting NCT05052853 - Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer Phase 2
Recruiting NCT05877716 - EPI-MINN: Targeting Cognition and Motivation - National N/A
Completed NCT01597141 - Psychosis: Early Detection, Intervention and Prevention N/A
Completed NCT00169988 - Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms N/A
Completed NCT06190483 - Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk N/A
Completed NCT01619319 - Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis N/A
Recruiting NCT05167396 - REtinal and VIsual Cortical Response in Early PSYchosis N/A
Terminated NCT00169949 - Aripiprazole Treatment of the Prodrome N/A
Recruiting NCT04338152 - Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial N/A
Recruiting NCT05142735 - Effects of NAC on Symptoms of CHR Patients N/A
Enrolling by invitation NCT05532683 - Feasibility Trial of a Lifestyle Intervention for CHR-P N/A
Enrolling by invitation NCT03970005 - Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis